ClinicalTrials.gg
Enrolling by invitationNCT00950430Updated Jun 23, 2026

Imaging of Brain Amyloid Plaques in the Aging Population

A Phase 4 interventional study of Pittsburgh Compound B (C-11 PiB) and F-18 FDG in Alzheimer's Disease, Dementia With Lewy Bodies and Frontotemporal Dementia, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 30 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,000
Allocation
Not applicable
Ages
30 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Alzheimer Disease by Mayo Clinic — 8 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Mayo Clinic.

Planned enrollment
Largest of 17
8,000 · median 57
Started
2008
the only one that year
Phase 4
2 of 21
2 open now
Registered
2nd of 21
by date

Among the 21 studies in Alzheimer Disease by Mayo Clinic, this one has the largest planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 4, and was the 2nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 21 studies in Alzheimer Disease by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 30 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Alzheimer Disease by Mayo Clinic, or all of them as a file.
02

Study summary

This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in amyloid burden over time, and concurrent change in clinical status.

Read the detailed description

Identification of risk factors and biomarkers of neurodegenerative disease is essential in caring for the growing numbers of elderly. Imaging biomarkers provide non-invasive ways to look at brain function. A new PET imaging agent, Pittsburgh Compound B (PiB), that identifies brain amyloid is an exciting development in brain imaging that needs to be studied. We plan to study this imaging technique in normal volunteers and patients with a variety of neurodegenerative diseases to determine its utility. Long term followup of these subjects will allow us to understand the predictive ability of this new test.

03

Conditions studied

  • Alzheimer's Disease
  • Dementia With Lewy Bodies
  • Frontotemporal Dementia
  • Vascular Dementia

Keywords

  • Imaging
  • PET
  • PiB
  • FDG
  • MCI
  • Dementia
  • Alzheimer's Disease
  • Brain Amyloid
04

Who can participate

Ages eligible
30 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30-100
  • Subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the Mayo Clinic Study of Aging, Mayo ADRC, or Mayo neurodegenerative disease clinics.

Exclusion criteria

Exclusion Criteria:

  • Subjects unable to lie down without moving for 10 minutes
  • Women who are pregnant or cannot stop breast feeding for 24 hours at the time of scanning
  • Claustrophobic patients unable to tolerate the scans
  • Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc.
05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8,000 participants (estimated)

Study arms

  • Experimental
    PiB PET, FDG PET, Tau PET

    Drug: Pittsburgh Compound B (C-11 PiB) · Drug: F-18 FDG · Drug: Tau (18-F-AV-1451)

Interventions

  • DrugPittsburgh compound BStudies of Pittsburgh compound BPittsburgh compound B pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.

  • DrugF-18 FDG

    Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.

  • DrugFlortaucipirStudies of FlortaucipirFlortaucipir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. PIB PET scan, Tau PET scan and/or FDG PET scan 2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan.

06

What researchers measure

Primary outcomes

  1. To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.

    Time frame: up to 20 years

Secondary outcomes

  1. Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.

    Time frame: up to 20 years

  2. To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.

    Time frame: up to 20 years

  3. To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.

    Time frame: up to 20 years

  4. To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.

    Time frame: up to 20 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jun 2027 and a completion of Jun 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2009
First posted
Jul 31, 2009
Start
Apr 2008
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00950430
Lead sponsor
Mayo Clinic
Responsible party
Val Lowe (Consultant - Diagnostic Radiology, Mayo Clinic) — Principal investigator
First posted
Jul 31, 2009
Start date
Apr 2008
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Val Lowe, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pittsburgh compound B

Start the discussion